Share this article
CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 shares of common stock, (ii) 1,000,000 pre-funded common stock Warrants (i.e., warrants to purchase shares of Qualigen common stock, for which the exercise price is almost entirely prepaid), (iii) 1,348,314 two-year common stock Warrants with an exercise price of $4.07 per share, and (iv) 842,696 common stock Warrants (first exercisable 6 months after issuance, and with an expiration date 30 months after issuance) with an exercise price of $4.07 per share.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology
December 15, 2020 GMT
CARLSBAD, Calif., Dec. 15, 2020 /PRNewswire/ Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, today announced that the United States Patent and Trademark Office has issued a patent entitled “Anti-Nucleolin Agent-Conjugated Nanoparticles as Radio-Sensitizers and/or MRI Contrast Agents” regarding the Company’s ALAN (Aptamer-Linked Anti-Nucleolin) technology. This patent issued to the University of Louisville (UofL) protects the ALAN technology for use with cancer radiation therapy and for imaging tumors utilizing magnetic resonance imaging (MRI). The novel ALAN technology has several other potential applications, including its use as